Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI).
Annibali O, Hohaus S, Marchesi F, Cantonetti M, Di Rocco A, Tomarchio V, Di Napoli A, Pelliccia S, Battistini R, Anticoli Borza P, Abruzzese E, Cenfra N, Andriani A, Tesei C, Alma E, Palombi F, Pupo L, Petrucci L, Becilli M, Maiolo E, Bellesi S, Cuccaro A, D'Alò F, Cox MC. Annibali O, et al. Among authors: marchesi f. Leuk Lymphoma. 2019 Dec;60(14):3386-3394. doi: 10.1080/10428194.2019.1633628. Epub 2019 Jul 1. Leuk Lymphoma. 2019. PMID: 31259651
A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment.
Marchesi F, Cenfra N, Altomare L, Dessanti ML, Mecarocci S, Cerchiara E, Rago A, D'Andrea M, Tomarchio V, Olimpieri OM, Tirindelli MC, Mengarelli A, Petti MC, Avvisati G, Cimino G. Marchesi F, et al. J Geriatr Oncol. 2013 Jul;4(3):242-8. doi: 10.1016/j.jgo.2013.04.003. Epub 2013 May 7. J Geriatr Oncol. 2013. PMID: 24070462
Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network.
Marchesi F, Cerchiara E, Dessanti ML, Gumenyuk S, Franceschini L, Palombi F, Pisani F, Romano A, Spadea A, Pupo L, Annibali O, La Malfa A, Arcese W, Mengarelli A. Marchesi F, et al. Br J Haematol. 2015 Apr;169(2):293-6. doi: 10.1111/bjh.13199. Epub 2014 Nov 5. Br J Haematol. 2015. PMID: 25371286 Free article. No abstract available.
Biosimilar filgrastim (Zarzio®) vs. lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience.
Marchesi F, Vacca M, Gumenyuk S, Pandolfi A, Renzi D, Palombi F, Pisani F, Romano A, Spadea A, Ipsevich F, Santinelli S, De Rienzo M, Papa E, Canfora M, Laurenzi L, Foddai ML, Pierelli L, Mengarelli A. Marchesi F, et al. Leuk Lymphoma. 2016 Feb;57(2):489-492. doi: 10.3109/10428194.2015.1063147. Epub 2015 Jul 18. Leuk Lymphoma. 2016. PMID: 26099572 No abstract available.
416 results